NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy

Description

This study will assess whole brain samples from glioblastoma patients at autopsy to determine the underlying pathological signatures of tumor treatment fields at autopsy.

Conditions

Glioblastoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will assess whole brain samples from glioblastoma patients at autopsy to determine the underlying pathological signatures of tumor treatment fields at autopsy.

NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy

NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy

Condition
Glioblastoma
Intervention / Treatment

-

Contacts and Locations

Milwaukee

Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States, 53226

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Newly diagnosed glioblastoma, World Health Organization (WHO) grade IV, patients undergoing TTField therapy.
  • * Recurrent glioblastoma WHO grade IV, patients undergoing TTField therapy.
  • * TTField compliance \< 75%.
  • * Any contraindication to Optune TTField treatment.
  • * Initial brain tumor diagnosis \< WHO grade IV.
  • * Duration of TTField therapy \< 3 months.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Medical College of Wisconsin,

Peter LaViolette, PhD, PRINCIPAL_INVESTIGATOR, Medical College of Wisconsin

Study Record Dates

2027-05-31